Antibiotics have significant and long-lasting impacts on the intestinal microbiota and consequently reduce colonization resistance against infection (CDI). Standard therapy using antibiotics is associated with a high rate of disease recurrence, highlighting the need for novel treatment strategies that target toxins, the major virulence factors, rather than the organism itself. Human monoclonal antibodies MK-3415A (actoxumab-bezlotoxumab) to toxin A and toxin B, as an emerging non-antibiotic approach, significantly reduced the recurrence of CDI in animal models and human clinical trials. Although the main mechanism of protection is through direct neutralization of the toxins, the impact of MK-3415A on gut microbiota and its restoration has not been examined. Using a CDI murine model, we compared the bacterial diversity of the gut microbiome of mice under different treatments including MK-3415A, vancomycin, or vancomycin combined with MK-3415A, sampled longitudinally. Here, we showed that infection resulted in the prevalence of species. Sixty percent of mice in the vehicle group died after 2 days and their microbiome was almost exclusively formed by . MK-3415A treatment resulted in lower levels and restoration of , and which were the core components of the original microbiota. Vancomycin treatment led to significantly lower survival rate than the combo treatment of MK-3415A and vancomycin. Vancomycin treatment decreased bacterial diversity with predominant and , while expanded after vancomycin treatment was terminated. In contrast, mice treated by vancomycin combined with MK-3415A also experienced decreased bacterial diversity during vancomycin treatment. However, these animals were able to recover their initial and proportions, even though episodes of overgrowth were detected by the end of the experiments. In conclusion, MK-3415A (actoxumab-bezlotoxumab) treatment facilitates normalization of the gut microbiota in CDI mice. It remains to be examined whether or not the prevention of recurrent CDI by the antitoxin antibodies observed in clinical trials occurs through modulation of microbiota.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5048712PMC
http://dx.doi.org/10.3389/fcimb.2016.00119DOI Listing

Publication Analysis

Top Keywords

vancomycin treatment
16
gut microbiota
12
bacterial diversity
12
treatment
9
antitoxin antibodies
8
actoxumab-bezlotoxumab treatment
8
treatment facilitates
8
facilitates normalization
8
normalization gut
8
mk-3415a
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!